{"schema_version":"secwatch.filing_event.v1","accession":"0001740797-23-000030","form_type":"8-K","ticker":"AVAI","cik":"0001740797","company_name":"AVAI BIO, INC.","filed_at":"2023-04-24T23:59:59+00:00","discovered_at":"2026-05-14T18:03:40.337519+00:00","generated_at":"2026-06-16T19:10:40.906897+00:00","sec_items":["1.01","3.02","5.02","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Trend Innovations names new CEO Kenneth Waggoner; ex-CEO Tunevic stays as President","bullets":["Kenneth L. Waggoner named CEO on Apr 20, 2023, replacing Natalija Tunevic who remains President and director.","Annual base salary of $720,000 in common stock, retroactively increased to $1,440,000 upon listing on a national exchange.","Shares paid quarterly: $180,000 per quarter divided by 20-day VWAP; $2,500/mo health plan also paid in shares.","Agreement term one year from April 20, 2023, auto-renewing; includes confidentiality, invention assignment, and indemnification.","Waggoner has 45 years experience, including as CEO of PharmaCyte Biotech (2013-2022) and partner at Brobeck."],"urls":{"canonical":"https://secwatch.observer/filing/0001740797-23-000030","json":"https://secwatch.observer/filing/0001740797-23-000030.json","markdown":"https://secwatch.observer/filing/0001740797-23-000030.md","text":"https://secwatch.observer/filing/0001740797-23-000030.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1740797/000174079723000030/0001740797-23-000030-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1740797/000174079723000030/tren8kceo.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-16T19:10:40.906897+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"0bb6d1af44","claim":"Natalija Tunevic departed as President at AVAI BIO, INC..","evidence_excerpt":"Natalija Tunevic resigned as CEO of the Company but will continue to serve as President and a director of the Company.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1740797/000174079723000030/0001740797-23-000030-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"resigned as CEO"},{"label":"Role","value":"President"}],"fact_type":"executive_change"},{"claim_id":"8316f05f4c","claim":"Kenneth L. Waggoner was appointed as Chief Executive Officer at AVAI BIO, INC..","evidence_excerpt":"On April 20, 2023, Trend Innovations Holding Inc. (the “Company”) and Kenneth L. Waggoner entered into an Executive Compensation Agreement pursuant to which Mr. Waggoner was retained as Chief Executive Officer.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1740797/000174079723000030/0001740797-23-000030-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"retained"},{"label":"Role","value":"Chief Executive Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}